• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

    2.980 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 2.980
    Bid (Size) 2.700 (2)
    Ask (Size) 3.080 (3)
    Prev. Close 2.980
    Today's Range 2.980 - 2.980
    52wk Range 1.720 - 15.70
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise
    The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform. 
    Via Stocktwits

    Performance

    YTD
    -37.9%
    -37.9%
    1 Month
    +8.4%
    +8.4%
    3 Month
    -29.0%
    -29.0%
    6 Month
    -48.7%
    -48.7%
    1 Year
    -50.8%
    -50.8%

    More News

    Read More
    Crude Oil Down 2%; D.R. Horton Earnings Top Views
    Via Benzinga
    Exposures Fossil Fuels
    Why InMed Pharmaceuticals (INM) Stock Is Skyrocketing
    Via Benzinga
    Dow Jumps 200 Points; 3M Posts Upbeat Q4 Results
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Fiscal 2024 Financial Results, Provides Business Update
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CBDNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market Growth
    Via Investor Brand Network
    Topics Cannabis
    Exposures Cannabis
    InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy
    Via Investor Brand Network
    InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901
    Via Investor Brand Network
    Why Wolfspeed Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Three U.S. Patent Issuances
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Crude Oil Falls; Palo Alto Networks Shares Jump After Q4 Earnings
    Via Benzinga
    Exposures Fossil Fuels
    Nasdaq Moves Lower; Medtronic Posts Upbeat Earnings
    Via Benzinga
    BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment
    Via Investor Brand Network
    InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday
    Via Benzinga
    US Stocks Mixed; Lowe's Cuts FY24 Forecast
    Via Benzinga
    BioMedNewsBreaks — InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089 Showing Great Promise in Treating AMD
    Via Investor Brand Network
    InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”
    Via CannabisNewsWire
    Topics Cannabis
    Exposures Cannabis
    InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”
    Via Investor Brand Network
    Topics Cannabis
    Exposures Cannabis
    BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD
    Via Investor Brand Network
    InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
    Via Investor Brand Network
    InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
    Via CannabisNewsWire
    The Rising Importance Of Minor Cannabinoids In The Growing Edible Market
    Via News Direct
    Topics Cannabis
    Exposures Cannabis
    BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Significant Improvements from INM-089 in AMD, Validates INM-901 as Potential AD Treatment
    Via Investor Brand Network

    Frequently Asked Questions

    Is InMed Pharmaceuticals Inc. - Common Shares publicly traded?
    Yes, InMed Pharmaceuticals Inc. - Common Shares is publicly traded.
    What exchange does InMed Pharmaceuticals Inc. - Common Shares trade on?
    InMed Pharmaceuticals Inc. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for InMed Pharmaceuticals Inc. - Common Shares?
    The ticker symbol for InMed Pharmaceuticals Inc. - Common Shares is INM on the Nasdaq Stock Market
    What is the current price of InMed Pharmaceuticals Inc. - Common Shares?
    The current price of InMed Pharmaceuticals Inc. - Common Shares is 2.980
    When was InMed Pharmaceuticals Inc. - Common Shares last traded?
    The last trade of InMed Pharmaceuticals Inc. - Common Shares was at 04/24/25 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.